SILVER SPRING, Md., Aug. 13, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it is providing shareholders with an update on the status of PharmaCyte Biotech’s preclinical studies to be conducted by Translational Drug Development (TD2) in Scottsdale, Arizona.
The CEO and President of PharmaCyte Biotech, Kenneth L. Waggoner, said, “In an effort to keep our shareholders informed on the very important preclinical studies to determine if PharmaCyte Biotech’s unique treatment of cancer can slow the accumulation of fluid in the abdomen, known as “malignant ascites,” that is characteristic of the growth of many abdominal tumors, including pancreatic cancer, we wanted to announce that the encapsulated cells that will be used in the preclinical studies have arrived in the U.S. These are the encapsulated calls capable of converting the anticancer prodrug ifosfamide into its cancer-killing form using the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology. With the arrival of the encapsulated cells, the preclinical studies are now slated to begin at TD2 the week of August 18, 2014.”
About PharmaCyte Biotech
PharmaCyte Biotech (NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves the widely used anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. PharmaCyte Biotech is also working towards clinical trials associated with the symptoms of advanced pancreatic cancer and other abdominal cancers.
PharmaCyte Biotech’s subsidiary, Medical Marijuana Sciences, is dedicated to the development of cancer treatments based upon chemical constituents of the Cannabis plant known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences an opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, that could cause actual results to differ materially from those set forth in the forward-looking statements include PharmaCyte Biotech’s ability to continue as a going concern, delays in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.nuvilex.com. It can also be obtained by contacting Investor Relations.
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 917.595.2856 Ext. 106
[email protected]
